NCT02856477终止不适用
Pharmacogenetic in the Therapeutic Strategy in Depressed Elderly
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- patient remission
研究概览
简要总结
The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients.
Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •current major depressive disorder
- •antidepressant treatment
排除标准
- •dextromethorphan contra-indication
- •other psychiatric disorder
- •kidney failure
- •liver failure mini mental State Examination (MMSE)<18
结局指标
主要结局
patient remission
时间窗: 6 months
remission is defined by a Montgomery and asberg depression rating (MADRS) score\<10.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Pharmacogenetic-Directed Treatment for Major DepressionDepressionNCT01261364Assurex Health Inc.50
已完成
不适用
A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of DepressionBipolarMood DisorderDepressionNCT02189057Mayo Clinic160
Unknown
不适用
Predict Antidepressant Responsiveness Using PharmacogenomicsDepressive SymptomsDepressionNCT01228357Samsung Medical Center1,000
Unknown
4 期
Pharmacogenomics Studies of AntidepressantsAntidepressive AgentsPharmacogeneticsVenlafaxineFluoxetineMajor Depressive DisorderNCT01204086National Cheng-Kung University Hospital200
已完成
不适用
Clinical Pharmacogenomics of Antidepressant ResponseDepressionNCT00384020National Health Research Institutes, Taiwan402